Key result
Transcriptomic analysis links 753 differentially expressed genes to Ewing sarcoma metastasis, including upregulated surfactant proteins.
Why the study?
Ewing sarcoma frequently recurs despite high initial treatment success, likely due to undetected micrometastatic disease at diagnosis, prompting characterization of transcriptomic differences between primary and metastatic disease.
Observational (n=119)
This study provides a computationally derived molecular profile of metastatic Ewing sarcoma, identifying candidate genes and pathways for future validation.
Supports exploration of surfactant proteins in metastatic Ewing sarcoma; leaves open therapeutic relevance pending validation.
Ewing sarcoma (ES) is a bone malignancy primarily, well known by its t(11;22)(q24;q12) chromosomal translocation. Despite high initial treatment success, ES frequently recurs, likely due to micrometastatic disease present at diagnosis but undetected during primary treatment. This study aims to characterize transcriptomic differences between primary and metastatic ES to identify genes and pathways associated with the metastatic phenotype. Using the Search Tag Analyze Resource for National Center for Biotechnology Information’s Gene Expression Omnibus, seven independent gene expression series were identified, yielding 37 metastatic and 82 primary ES tumor samples. Differentially expressed genes were defined using a significance threshold of p < 0.05 and absolute experimental log ratio > 0.1 and were analyzed using Ingenuity Pathway Analysis. This integrative transcriptomic analysis identified 753 significant molecules. Metastatic ES was characterized by upregulation of lung-associated surfactant proteins and secretoglobin family members, along with downregulation of genes involved in extracellular matrix organization. Additional genes of interest included SLC6A14, CXCL14, and TBX3, which have been implicated in tumor progression in other malignancies. These findings provide a computationally derived molecular profile associated with metastatic ES and highlight candidate genes and pathways that warrant further validation. This integrative approach offers a framework for future studies focused on understanding metastatic biology in rare pediatric cancers.
No takes yet. Share an insight, caveat, or question.
Mitchell et al. (2026) conducted an observational in Ewing sarcoma (n=119). Metastatic Ewing sarcoma vs. Primary Ewing sarcoma was evaluated on Differentially expressed genes. Integrative transcriptomic analysis of 119 Ewing sarcoma samples identified 753 differentially expressed genes between metastatic and primary tumors, including upregulation of surfactant proteins.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: